Aratana Therapeutics Company Profile (NASDAQ:PETX)

About Aratana Therapeutics

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PETX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.50
  • 50 Day Moving Average: $7.36
  • 200 Day Moving Average: $8.20
  • 52-Week Range: $3.15 - $10.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.42
  • P/E Growth: -0.61
  • Market Cap: $240.79M
  • Outstanding Shares: 37,044,000
  • Beta: 3.65
Profitability:
  • Net Margins: -60.32%
  • Return on Equity: -19.87%
  • Return on Assets: -13.14%
Debt:
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 5.18%
  • Quick Ratio: 4.92%
Additional Links:
Companies Related to Aratana Therapeutics:

Analyst Ratings

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $10.50 (61.54% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2017William BlairReiterated RatingOutperformView Rating Details
2/6/2017Stifel NicolausDowngradeBuy -> Hold$8.00View Rating Details
11/18/2016Jefferies Group LLCReiterated RatingBuy$13.00 -> $11.00View Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$15.00View Rating Details
8/11/2016Barclays PLCLower Price TargetOverweight$15.00 -> $11.00View Rating Details
8/10/2016Credit Suisse GroupReiterated RatingBuy$11.00View Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00View Rating Details
11/4/2015Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $15.00View Rating Details
2/25/2015JMP SecuritiesSet Price TargetBuy$38.00View Rating Details
2/25/2015Bank of America CorpBoost Price Target$26.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Aratana Therapeutics (NASDAQ:PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/3/2016Q316($0.48)($0.38)$0.08 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)ViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-1.20 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.40)($0.41)
Q2 20162($0.43)($0.41)($0.42)
Q3 20163($0.48)($0.40)($0.44)
Q4 20163($0.41)($0.38)($0.40)
Q1 20172($0.35)($0.27)($0.31)
Q2 20171($0.33)($0.33)($0.33)
Q3 20172($0.30)($0.22)($0.26)
Q4 20172($0.27)($0.12)($0.20)
Q1 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 75.44%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.00View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
DateHeadline
finance.yahoo.com logoAratana Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:PETX)
finance.yahoo.com - February 22 at 7:18 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aratana Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 7, 2017 – PETX (NASDAQ:PETX)
finance.yahoo.com - February 22 at 7:18 PM
finance.yahoo.com logoSHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 22 at 7:18 PM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 22 at 9:15 AM
businesswire.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. To Contact Brower Piven Before The Lead ... (NASDAQ:PETX)
www.businesswire.com - February 21 at 5:42 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) and Lead Plaintiff Deadline: April 7, 2017 (NASDAQ:PETX)
finance.yahoo.com - February 21 at 5:42 PM
finance.yahoo.com logoINVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 21 at 5:42 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:PETX)
finance.yahoo.com - February 21 at 5:42 PM
4-traders.com logoLundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
www.4-traders.com - February 17 at 4:51 PM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Aratana Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 7, 2017 - PETX (NASDAQ:PETX)
us.rd.yahoo.com - February 17 at 4:51 PM
News IconShares in Focus: Aratana Therapeutics Inc. (PETX) - BVN (NASDAQ:PETX)
bvnewsjournal.com - February 16 at 11:45 PM
News IconAratana Therapeutics Inc (NASDAQ:PETX) Investor Lawsuit Alleges Misleading Statements (NASDAQ:PETX)
www.ssuchronicle.com - February 16 at 6:45 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) and Lead Plaintiff Deadline - April 7, 2017 (NASDAQ:PETX)
us.rd.yahoo.com - February 16 at 6:45 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 14 at 11:20 PM
News IconTechnical Roundup on Shares of Aratana Therapeutics Inc. (PETX) - Baldwin Journal (NASDAQ:PETX)
baldwinjournal.com - February 14 at 3:04 AM
businesswire.com logoPETX LOSS NOTICE: Rosen Law Firm Reminds Aratana Therapeutics, Inc. Investors of Important Deadline in Class ... - Business Wire (press release) (NASDAQ:PETX)
www.businesswire.com - February 14 at 3:04 AM
finance.yahoo.com logoPETX LOSS NOTICE: Rosen Law Firm Reminds Aratana Therapeutics, Inc. Investors of Important Deadline in Class Action – PETX (NASDAQ:PETX)
finance.yahoo.com - February 14 at 3:04 AM
finance.yahoo.com logoPETX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Aratana Therapeutics, Inc. and a Lead Plaintiff Deadline of April 7, 2017 (NASDAQ:PETX)
finance.yahoo.com - February 13 at 10:04 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 12 at 8:38 AM
einnews.com logoFlorida Panthers score 4 in 2nd period, beat Predators 7-4 (NASDAQ:PETX)
uspolitics.einnews.com - February 11 at 7:16 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. (PETX) To Contact Brower Piven Before The Lead Plaintiff Dea (NASDAQ:PETX)
finance.yahoo.com - February 11 at 7:16 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. (PETX) To Contact Brower Piven Before The Lead Plaintiff Deadline (NASDAQ:PETX)
feeds.benzinga.com - February 11 at 7:47 AM
globenewswire.com logoIMPORTANT ARATANA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP ... - GlobeNewswire (press release) (NASDAQ:PETX)
globenewswire.com - February 10 at 8:09 PM
globenewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aratana ... - GlobeNewswire (press release) (NASDAQ:PETX)
globenewswire.com - February 10 at 8:09 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 10 at 8:09 PM
News IconKhang & Khang LLP Announces an Investigation claims against Aratana Therapeutics, Inc. (PETX) (NASDAQ:PETX)
xboxonezone.com - February 9 at 9:05 PM
us.rd.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. (NASDAQ:PETX)
us.rd.yahoo.com - February 9 at 9:05 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) & Lead Plaintiff Deadline - April 7, 2017 (NASDAQ:PETX)
us.rd.yahoo.com - February 9 at 9:05 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Aratana Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 7, 2017 – PETX (NASDAQ:PETX)
us.rd.yahoo.com - February 9 at 9:05 PM
us.rd.yahoo.com logoPawar Law Group Announces Filing of a Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. - PETX (NASDAQ:PETX)
us.rd.yahoo.com - February 9 at 9:05 PM
finance.yahoo.com logoIMPORTANT ARATANA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York against Aratana Therapeutics, Inc. (NASDAQ:PETX)
finance.yahoo.com - February 9 at 9:05 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 9 at 9:05 PM
businesswire.com logoPETX INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics ... - Business Wire (press release) (NASDAQ:PETX)
www.businesswire.com - February 9 at 1:11 AM
finance.yahoo.com logoPETX INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 8 at 8:09 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aratana Therapeutics, Inc ... - Yahoo Finance (NASDAQ:PETX)
finance.yahoo.com - February 7 at 8:30 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Aratana ... - PR Newswire (press release) (NASDAQ:PETX)
www.prnewswire.com - February 7 at 8:30 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aratana Therapeutics, Inc ... - PR Newswire (press release) (NASDAQ:PETX)
www.prnewswire.com - February 7 at 8:30 PM
smarteranalyst.com logoWilliam Blair Bullish on Aratana Therapeutics Inc (PETX) Despite Delayed Commercial Launch for Entyce - Smarter Analyst (NASDAQ:PETX)
www.smarteranalyst.com - February 7 at 8:29 PM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aratana Therapeutics, Inc. (PETX) (NASDAQ:PETX)
finance.yahoo.com - February 7 at 8:29 PM
rttnews.com logoAratana Therapeutics Inc. (PETX) Fell To A 6-Month Low On Entyce News (NASDAQ:PETX)
www.rttnews.com - February 7 at 8:57 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Aratana Therapeutics, Inc., and Encourages Investors to Contact the Firm (NASDAQ:PETX)
finance.yahoo.com - February 7 at 12:18 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aratana ... (NASDAQ:PETX)
www.businesswire.com - February 6 at 7:15 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aratana Therapeutics, Inc. - PETX (NASDAQ:PETX)
us.rd.yahoo.com - February 6 at 7:15 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aratana Therapeutics, Inc. (PETX) (NASDAQ:PETX)
us.rd.yahoo.com - February 6 at 7:15 PM
fool.com logoWhy Aratana Therapeutics Inc. Is Tumbling Today (NASDAQ:PETX)
us.rd.yahoo.com - February 6 at 7:15 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aratana Therapeutics, Inc. -- PETX (NASDAQ:PETX)
us.rd.yahoo.com - February 6 at 7:15 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Aratana Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm (NASDAQ:PETX)
us.rd.yahoo.com - February 6 at 7:15 PM
us.rd.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Aratana Therapeutics, Inc. - PETX (NASDAQ:PETX)
us.rd.yahoo.com - February 6 at 7:15 PM
feeds.benzinga.com logoPomerantz Law Firm Announces the Filing of a Class Action against Aratana Therapeutics, Inc. and Certain Officers – PETX (NASDAQ:PETX)
feeds.benzinga.com - February 6 at 6:24 PM
marketwatch.com logoAratana Therapeutics' stock tumbles after delay to commercialize pet drug (NASDAQ:PETX)
www.marketwatch.com - February 6 at 9:11 AM

Social

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2017?

7 equities research analysts have issued twelve-month price targets for Aratana Therapeutics' stock. Their predictions range from $7.00 to $15.00. On average, they anticipate Aratana Therapeutics' share price to reach $10.50 in the next twelve months.

When will Aratana Therapeutics announce their earnings?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:

  • According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (2/9/2017)

  • Stifel Nicolaus analysts commented, "Friday evening, Aratana announced that the launch of ENTYCE (capromorelin oral solution to treat inappetence for dogs) will be pushed out to late 2017 versus prior expectations of 1Q17. While the modest delay does not materially alter our peak sales expectations, it is the latest in a series of setbacks that have weighed on the company. In September 2015, Aratana's canine lymphoma initiative hit a meaningful roadblock, causing us to significantly curtail future sales expectations. More recently, a couple of other indications have taken longer to get to market due to resets with pilot studies (feline and AT-018), been de-prioritized (AT-007 feline immunodeficiency virus), or eliminated altogether (AT-011 canine parvovirus). The latest setback with ENTYCE is related to production/commercialization, and when combined with prior speed bumps, pushes the company's commercial sales traction out to 2018 (ENTYCE previously accounted for 75% of our 2017E sales). In our opinion, Aratana's story has subtly changed from that of revenue diversification (handful of drugs each accounting for 10-20% of sales) to one that is concentrated, with two drugs accounting for the majority of future sales. With this in mind, and the latest commercial setback which has now caused us to take a more conservative stance around the timeline for other indications, we downgrade to Hold (lower TP from $11 to $8) and wait for better visibility in the coming quarters (canine NOCITA and ENTYCE sales ramp, feline clinical initiatives)." (2/6/2017)

Who owns Aratana Therapeutics stock?

Aratana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (14.54%), Broadfin Capital LLC (9.98%), Janus Capital Management LLC (3.85%), State Street Corp (1.76%), First Light Asset Management LLC (1.11%) and Oxford Asset Management (0.67%). Company insiders that own Aratana Therapeutics stock include Craig A Tooman, Ernst Heinen, Julia A Stephanus, Linda Rhodes, Peter Steven St and Vort John Vander.

Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?

Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Turner Investments LLC, First Light Asset Management LLC, Wall Street Associates, Oxford Asset Management, Numeric Investors LLC, State Street Corp, Renaissance Technologies LLC and Franklin Resources Inc.. Company insiders that have sold Aratana Therapeutics stock in the last year include Craig A Tooman, Ernst Heinen, Julia A Stephanus and Peter Steven St.

Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?

Aratana Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Broadfin Capital LLC, Dimensional Fund Advisors LP, AQR Capital Management LLC, A.R.T. Advisors LLC, Cadence Capital Management LLC, Baird Financial Group Inc. and Redmond Asset Management LLC.

How do I buy Aratana Therapeutics stock?

Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aratana Therapeutics stock cost?

One share of Aratana Therapeutics stock can currently be purchased for approximately $6.50.

Aratana Therapeutics (NASDAQ:PETX) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Earnings History Chart

Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Dividend History Chart

Dividend Payments by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Last Updated on 2/23/2017 by MarketBeat.com Staff